V Guan Finance Report ｜ Zixin Pharmaceutical and many subsidiaries have become "Lao Lai", which lost nearly 1 billion last year

Zhongxin Jingwei, July 18th. Zixin Pharmaceutical issued an announcement on the 18th of the company and some subsidiaries.

The announcement shows that the company recently implemented the information disclosure network in China and learned that the company and related subsidiaries Jilin Caojia Dan Pharmaceutical Co., Ltd., Jilin Zixin Prajna Pharmaceutical Co., Ltd., and Jilin Zixin Pharmaceutical Co., Ltd. The person was listed as a dishonesty by the relevant court. Among them, (2021) Anhui 1602 held No. 5979 showing that Zixin Pharmaceuticals, Cao Hui Dan Pharmaceuticals, Zixin Prajna, and Zixin Yuzhuo refused to fulfill the obligation to perform effective legal documents.

Announce screenshot

Regarding the subsequent impact, Zixin Pharmaceutical said that the company and related subsidiaries have been included in the list of people who have been incorporated into the company and related subsidiaries. The company will adopt proper solutions to deal with the above matters as soon as possible. At the same time And the subsidiaries will make every effort to raise debt repayment by accelerating the recovery of account receivables and disposal assets. The incident of being incorporated into the dishonesty and being executed has not yet caused a significant impact on the company's normal operation. The company will continue to pay attention to the progress of the matter and timely fulfill the information disclosure obligation.

Founded in May 1998, Zixin Pharmaceutical is a high -tech joint -stock enterprise integrating scientific research, development, production, sales, and medicinal animal and plant breeding. It is mainly engaged in the research and development, production, sales and traditional Chinese medicine planting business of Chinese medicine. The main products include promoting blood circulation, musk -connecting bone capsules, wake -up reinforcement capsules, and Simiao pills. It was listed on the Shenzhen Stock Exchange on March 2, 2007. Its legal representative is Lu Yan.

Zixin Pharmaceutical was once known as the "king of ginseng", but in recent years, as the ginseng market is no longer hot, Zixin Pharmaceutical has gradually trapped in debt quagmires.

On August 7, 2021, Zixin Pharmaceutical issued an announcement saying that the company and subsidiary's debt overdue was as high as 2.513 billion yuan, and the mobile funds were tight, and the arrears of wages, tax arrears, and interest rates occurred.

The financial report in 2021 shows that Zixin Pharmaceutical's operating income was 247 million yuan, a year -on -year decrease of 13.57%; net loss attributable to shareholders of listed companies was 998 million yuan, an increase of 41.43%year -on -year. In the first quarter of this year, operating income was 6.9792 million yuan, a year -on -year decrease of 88.69%; net profit attributable to the owner of the parent company was 207 million yuan, and the net loss of 99.772 million yuan in the same period last year.

In the secondary market, Zixin Pharmaceutical rose 2.33%on the 18th to close at 2.64 yuan/share, with a market value of 3.4 billion yuan. (Zhongxin Jingwei APP)

- END -